U.S. markets closed

RAPT Therapeutics, Inc. (RAPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.73+0.58 (+3.20%)
At close: 4:00PM EST

18.73 0.00 (0.00%)
After hours: 6:29PM EST

RAPT Therapeutics, Inc.

561 Eccles Avenue
South San Francisco, CA 94080
United States
650 489 9000

Full Time Employees71

Key Executives

NameTitlePayExercisedYear Born
Dr. Brian Russell WongCEO, Pres & Director912.2kN/A1972
Mr. Rodney K. B. YoungCFO & Sec.132.08kN/A1963
Dr. Dirk G. Brockstedt Ph.D.Chief Scientific Officer427.77kN/A1969
Ms. Karen C. LamVP of Fin. & Corp. Controller and Principal Accounting OfficerN/AN/A1974
Steve Young Ph.D.VP of TechnologyN/AN/AN/A
Ms. Phyllis Loud GrayVP of HRN/AN/AN/A
Dr. Paul KassnerSr. VP of Quantitative & Computational BiologyN/AN/A1967
Dr. David WustrowSr. VP of Drug Discovery & Preclinical Devel.N/AN/A1959
Dr. William HoChief Medical OfficerN/AN/A1965
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

RAPT Therapeutics, Inc.’s ISS Governance QualityScore as of December 2, 2020 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.